Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) COO Ganesh Venkataraman Kaundinya sold 1,917 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $16.00, for a total value of $30,672.00. Following the completion of the sale, the chief operating officer now directly owns 492,845 shares of the company’s stock, valued at $7,885,520. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Ganesh Venkataraman Kaundinya also recently made the following trade(s):

  • On Tuesday, November 21st, Ganesh Venkataraman Kaundinya sold 821 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $13.15, for a total value of $10,796.15.

Momenta Pharmaceuticals, Inc. (MNTA) opened at $16.00 on Wednesday. The firm has a market capitalization of $1,220.00, a price-to-earnings ratio of -20.00 and a beta of 1.80. Momenta Pharmaceuticals, Inc. has a twelve month low of $11.85 and a twelve month high of $19.46.

Institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its holdings in Momenta Pharmaceuticals by 14.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 6,446 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 834 shares during the period. LS Investment Advisors LLC boosted its holdings in Momenta Pharmaceuticals by 59.8% during the 4th quarter. LS Investment Advisors LLC now owns 9,300 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 3,479 shares during the period. Amalgamated Bank purchased a new position in Momenta Pharmaceuticals during the 4th quarter valued at about $152,000. Landscape Capital Management L.L.C. purchased a new position in Momenta Pharmaceuticals during the 4th quarter valued at about $159,000. Finally, Citigroup Inc. boosted its holdings in Momenta Pharmaceuticals by 263.2% during the 2nd quarter. Citigroup Inc. now owns 13,736 shares of the biotechnology company’s stock valued at $232,000 after acquiring an additional 9,954 shares during the period. Institutional investors own 93.01% of the company’s stock.

A number of equities analysts have recently weighed in on the company. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday. Stifel Nicolaus reiterated a “hold” rating and set a $18.00 price target on shares of Momenta Pharmaceuticals in a report on Tuesday, January 30th. Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, Cowen set a $15.00 price target on Momenta Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $15.30.

COPYRIGHT VIOLATION WARNING: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2018/02/14/ganesh-venkataraman-kaundinya-sells-1917-shares-of-momenta-pharmaceuticals-inc-mnta-stock.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.